Everyone is so focused on Humira's patent cliff, but they're missing the bigger picture here. AbbVie has been on a tear acquiring new assets and their pipeline, especially Skyrizi and Rinvoq, is absolutely stacked to drive future growth. Plus, that dividend has been consistently raised for years, so you can get paid to hold while the rest of the market catches on.

BUY.